From improved glycemic control and weight management to cardiovascular benefits, blood pressure regulation, and potential impacts on liver health, neuroprotection, and gastrointestinal function, semaglutide represents a multifaceted treatment option
Several of these drugs (exenatide (Byetta and Bydureon), liraglutide (Victoza for diabetes, Saxenda for obesity) albiglutide (Tanzeum), dulaglutide (Trulicity), and lixisenatide (Lyxumia in Europe, Adlyxin in the United States) have been around for at least ten years
Common adverse effects include nausea, vomiting, diarrhoea, injection site reactions, and increased heart rate, particularly during dose escalation
In short, there are several reasons why more people and providers are experimenting with microdosing, ranging from cost and access challenges to adverse side effects at standard doses, as well as off-label uses such as appetite suppression, management of acute and chronic inflammation, impulse control, and adjunctive support in type 1 diabetes